The cost-effectiveness acceptability curves stratified by Patient Assistance Program (PAP) in comparison with conventional therapy (top) and imatinib switch conventional therapy (bottom). The y-axis indicates the probability that a strategy is cost-effective across the willingness to pay threshold per QALY gained (x-axis).